NCT00453713

Brief Summary

The purpose of this study is to identify factors that contribute to higher mortality rates among blacks and Hispanics with diffuse parenchymal lung disease.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
565

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2006

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2006

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

March 27, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 29, 2007

Completed
6.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2013

Completed
Last Updated

April 21, 2015

Status Verified

April 1, 2015

Enrollment Period

7.1 years

First QC Date

March 27, 2007

Last Update Submit

April 20, 2015

Conditions

Idiopathic Pulmonary FibrosisInterstitial Lung DiseaseDiffuse Parenchymal Lung Disease

Keywords

Idiopathic pulmonary fibrosisInterstitial lung diseaseDiffuse parenchymal lung diseaseHealth disparities

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Diffuse parenchymal lung disease

You may qualify if:

  • Diagnosis of IPF or other DPLD according to ATS criteria
  • Signed informed consent

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Columbia University Medical Center

New York, New York, 10032, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

Plasma/serum, DNA, and circulating cells and endothelial microparticles will be collected and processed.

MeSH Terms

Conditions

Idiopathic Pulmonary FibrosisLung Diseases, Interstitial

Condition Hierarchy (Ancestors)

Pulmonary FibrosisLung DiseasesRespiratory Tract Diseases

Study Officials

  • David J Lederer, M.D.

    Columbia University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Irving Assistant Professor of Medicine (in Pediatrics)

Study Record Dates

First Submitted

March 27, 2007

First Posted

March 29, 2007

Study Start

July 1, 2006

Primary Completion

August 1, 2013

Study Completion

August 1, 2013

Last Updated

April 21, 2015

Record last verified: 2015-04

Locations

US(1)